CENTOGENE Reports First Half 2020 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the […]
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants […]
DraftKings Appoints Two New Members to the Company’s Board of Directors
BOSTON, Sept. 23, 2020 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) today announced that the Company’s Board of Directors (the […]
TSX News -
AGF and the SAF Group Extend Partnership with Focus on New Private Credit Opportunities
AGF Management Limited Enters into Definitive Option Agreement with the SAF GroupTORONTO, Sept. 23, 2020 (GLOBE NEWSWIRE) — AGF Management […]
TSX News -
Magnetic Survey Reveals Multiple Large Scale Marimaca Style Targets and New IOCG District Potential
VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (“Marimaca Copper” or the “Company”) (TSX: MARI) is […]
BC Craft Supply Co Introduces Island Pinkhead From BC Micro Cultivator Dunn Cannabis Inc
VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) — BC Craft Supply Co. Ltd. (the “Company” or “BC Craft”) (CSE:CRFT) […]
BetterLife Provides Update on OTC Trading Activity
VANCOUVER, Sept. 23, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / […]
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is […]
Akoustis Receives XBAW RF Filter Design Win and Order from New 5G Small Cell Infrastructure Customer
– Band n79 Filter for New Small Cell Product Aimed at 5G Network Operators –– Akoustis Expects Production Ramp in […]
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease
Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL […]
